Effect of ubiquitin-specific protease on radiosensitivity of tumor

Abstract

Zhou Qifen, Wu Chunlin. Effect of ubiquitin-specific protease on radiosensitivity of tumor[J]. Journal of International Oncology, 2019, 46(7): 420-422.

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394424. DOI: 10.3322/caac.21492. ［2］ Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology［J］. Lancet Oncol, 2018, 19(5): e240e251. DOI: 10.1016/S14702045(18)300962. ［3］ de Poot SAH, Tian G, Finley D. Meddling with fate: the proteasomal deubiquitinating enzymes［J］. J Mol Biol, 2017, 429(22): 35253545. DOI: 10.1016/j.jmb.2017.09.015. ［4］ Wieringa HW, van der Zee AG, de Vries EG, et al. Breaking the DNA damage response to improve cervical cancer treatment［J］. Cancer Treat Rev, 2016, 42: 3040. DOI: 10.1016/j.ctrv.2015.11.008. ［5］ Wang Z, Zhang H, Liu J, et al. USP51 deubiquitylates H2AK13, 15ub and regulates DNA damage response［J］. Genes Dev, 2016, 30(8): 946959. DOI: 10.1101/gad.271841.115. ［6］ Zhang L, Nemzow L, Chen H, et al. The deubiquitinating enzyme USP24 is a regulator of the UV damage response［J］. Cell Rep, 2015, 10(2): 140147. DOI: 10.1016/j.celrep.2014.12.024. ［7］ Zhang W, Sartori MA, Makhnevych T, et al. Generation and validation of intracellular ubiquitin variant inhibitors for USP7 and USP10［J］. J Mol Biol, 2017, 429(22): 35463560. DOI: 10.1016/j.jmb.2017.05.025. ［8］ Liu J, Kruswick A, Dang H, et al. Ubiquitinspecific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth［J］. Nat Commun, 2017, 8(1): 137149. DOI: 10.1038/s41467017002062. ［9］ PerezOliva AB, Lachaud C, Szyniarowski P, et al. USP45 deubiquitylase controls ERCC1XPF endonucleasemediated DNA damage responses［J］. EMBO J, 2015, 34(3): 326343. DOI: 10.15252/embj.201489184. ［10］ Li Y, Huang W, Xu Y, et al. CYLD deubiquitinase negatively regulates high glucoseinduced NFkappaB inflammatory signaling in mesangial cells［J］. Biomed Res Int, 2017, 2017: 3982906. DOI: 10.1155/2017/3982906. ［11］ Liu C, Wang L, Chen W, et al. USP35 activated by miR let7a inhibits cell proliferation and NFκB activation through stabilization of ABIN2［J］. Oncotarget, 2015, 6(29): 2789127906. DOI: 10.18632/oncotarget.4451. ［12］ Poalas K, Hatchi EM, Cordeiro N, et al. Negative regulation of NFκB signaling in T lymphocytes by the ubiquitinspecific protease USP34［J］. Cell Commun Signal, 2013, 11(1): 25. DOI: 10.1186/1478811X1125. ［13］ Li G, Wang Z, Chong T, et al. Curcumin enhances the radiosensitivity of renal cancer cells by suppressing NFκB signaling pathway［J］. Biomed Pharmacother, 2017, 94: 974981. DOI: 10.1016/j.biopha.2017.07.148. ［14］ Ren K, Li Z, Li Y, et al. Sulforaphene enhances radiosensitivity of hepatocellular carcinoma through suppression of the NFκB pathway［J］. J Biochem Mol Toxicol, 2017, 31(8): e21917. DOI: 10.1002/jbt.21917. ［15］ Villeneuve NF, Tian W, Wu T, et al. USP15 negatively regulates Nrf2 through deubiquitination of Keap1［J］. Mol Cell, 2013, 51(1): 6879. DOI: 10.1016/j.molcel.2013.04.022. ［16］ Boustani MR, Khoshnood RJ, Nikpasand F, et al. Overexpression of ubiquitinspecific protease 2a (USP2a) and nuclear factor erythroid 2related factor 2 (Nrf2) in human gliomas［J］. J Neurol Sci, 2016, 363: 249252. DOI: 10.1016/j.jns.2016.03.003. ［17］ Hou K, Zhu Z, Wang Y, et al. Overexpression and biological function of ubiquitinspecific protease 42 in gastric cancer［J］. PLoS One, 2016, 11(3): e0152997. DOI: 10.1371/journal.pone.0152997. ［18］ Hu W, Wei H, Li K, et al. Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer［J］. Cell Prolif, 2017, 50(4): e12343. DOI: 10.1111/cpr.12343. ［19］ Kim J, D′annibale S, Magliozzi R, et al. USP17and SCFβTrCPregulated degradation of DEC1 controls the DNA damage response［J］. Mol Cell Biol, 2014, 34(22): 41774185. DOI: 10.1128/MCB.0053014. ［20］ McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC［J］. Cold Spring Harb Perspect Med, 2014, 4(10). pii: a014266. DOI: 10.1101/cshperspect.a014266. ［21］ Diefenbacher ME, Popov N, Blake SM, et al. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer［J］. J Clin Invest, 2014, 124(8): 34073418. DOI: 10.1172/JCI73733. ［22］ Pan J, Deng Q, Jiang C, et al. USP37 directly deubiquitinates and stabilizes cMyc in lung cancer［J］. Oncogene, 2015, 34(30): 39573967. DOI: 10.1038/onc.2014.327. ［23］ Sun XX, He X, Yin L, et al. The nucleolar ubiquitinspecific protease USP36 deubiquitinates and stabilizes cMyc［J］. Proc Natl Acad Sci U S A, 2015, 112(12): 37343739. DOI: 10.1073/pnas.1411713112.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Effect of ubiquitin-specific protease on radiosensitivity of tumor

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments